Simmondsin was modified with acarviosine-glucose using the transglycosylation activity of Thermus maltogenic amylase to synthesize a novel compound with both antiobesity and hypoglycemic activity. The LC/MS and 13C NMR analyses confirmed that the structure of the major transglycosylation product was acarviosine-simmondsin (Acv-simmondsin), in which acarviosine was attached to the glucose moiety of simmondsin by an α-(1,6)-glycosidic linkage. It was found that Acv-simmondsin was a potent competitive inhibitor of α-glucosidase with the Ki value of 0.69 μM and a mixed type inhibitor of α-amylase with the Ki and KI of 20.78 μM and 26.31 μM, respectively. The administration of Acv-simmondsin (0.1 g/100 g diet/day) to mice for 5 days significantly reduced food intake by 35%, compared to 25% with simmondsin in control obese mice. Acv-simmondsin (50 mg/kg BW) suppressed the postprandial blood glucose response to sucrose (1 g/kg BW) by 74%, compared to 71% with acarbose, in normal rats. © 2003 by Japan Society for Bioscience, Biotechnology, and Agrochemistry.
CITATION STYLE
Baek, J. S., Kim, H. Y., Abbott, T. P., Moon, T. W., Lee, S. B., Park, C. S., & Park, K. H. (2003). Acarviosine-simmondsin, a novel compound obtained from acarviosine-glucose and simmondsin by thermus maltogenic amylase and its in vivo effect on food intake and hyperglycemia. Bioscience, Biotechnology and Biochemistry, 67(3), 532–539. https://doi.org/10.1271/bbb.67.532
Mendeley helps you to discover research relevant for your work.